전신 마취제 시장 : 기회, 성장 촉진요인, 산업 동향 분석(2025-2034년)

The Global General Anesthesia Drugs Market, valued at USD 5.4 billion in 2024, is poised to grow at a steady CAGR of 3.6% from 2025 to 2034. General anesthesia drugs play an indispensable role in modern medicine, facilitating a controlled, reversible state of unconsciousness essential for a wide array of surgical procedures. As global healthcare systems continue to advance, the demand for effective anesthesia drugs is rising alongside increased surgical volumes, driven by aging populations, expanding healthcare access, and advancements in minimally invasive techniques. Innovations in anesthesia drug formulations, designed to enhance patient safety and optimize recovery times, further fuel this market's growth.

Key players in the market focus on extensive clinical research and development to improve the safety profiles and efficacy of anesthesia drugs, ensuring their readiness to meet the growing surgical demand. The push for patient-centric healthcare solutions also drives investments in anesthetics that offer rapid onset, short duration of action, and minimal side effects, making them suitable for outpatient and same-day procedures. These developments are expected to bolster the global market, cementing its critical role in supporting surgical and diagnostic advancements.

The market encompasses various drugs, including sevoflurane, propofol, dexmedetomidine, remifentanil, desflurane, midazolam, ketamine, and others. Among these, propofol emerged as the leading drug in 2024, capturing 27.5% of the market share. Renowned for its rapid onset, short duration of action, and smooth recovery profile, propofol remains a preferred choice for general anesthesia, particularly in outpatient settings. Its well-documented safety and efficacy, coupled with widespread regulatory approvals, have established propofol as a cornerstone in modern anesthetic practices.

From an application perspective, the general anesthesia drugs market is segmented into neurological, cardiovascular, orthopedic, and other surgeries. Orthopedic surgeries led the market in 2024, generating USD 2 billion in revenue. The rising prevalence of musculoskeletal disorders and the increasing adoption of minimally invasive surgical techniques, such as arthroscopy, have heightened the demand for general anesthesia in this segment. General anesthesia ensures optimal muscle relaxation and sedation, which are critical for the success of such procedures. As these techniques become more accessible, the demand for anesthesia drugs will continue to rise, driving overall market growth.

The United States is expected to dominate the market, with projections indicating a valuation of USD 3.2 billion by 2034. This expansion is fueled by the growing number of complex and routine surgeries across specialties like cardiovascular, neurological, and orthopedic disciplines. The steady increase in both elective and emergency surgical procedures underscores the need for reliable and effective anesthesia drugs, ensuring patient safety and contributing to the sustained growth of the market in this region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing volume of surgical procedures
    • 3.2.1.2 Advancements in anesthesia technology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
    • 3.2.2.2 Regulatory and compliance challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Sevoflurane
• 5.3 Propofol
• 5.4 Dexmedetomidine
• 5.5 Remifentanil
• 5.6 Desflurane
• 5.7 Midazolam
• 5.8 Ketamine
• 5.9 Other drugs

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Intravenous
• 6.3 Inhalational

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Neurological surgery
• 7.3 Cardiovascular surgery
• 7.4 Orthopedic surgery
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory surgical centers
• 8.4 Specialty clinics

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AbbVie
• 10.3 AstraZeneca plc
• 10.4 B. Braun Melsungen AG
• 10.5 Baxter International Inc.
• 10.6 Eisai Co.
• 10.7 Fresenius SE & Co. KGaA
• 10.8 Hikma Pharmaceuticals
• 10.9 Hikma Pharmaceuticals
• 10.10 Novartis AG
• 10.11 Par Pharmaceutical
• 10.12 Pfizer
• 10.13 Piramal Critical Care
• 10.14 Teva Pharmaceutical Industries
• 10.15 Viatris